PDF factsheet
      Z

antiplatelets drug in cardiovascular prevention for all type of patients, clinical trials results

aspirin versus no treatment
British Doctor’s Trial, 1988
aspirin 500 mg/d
versus
no aspirin
apparently healthy male doctorsopen
Follow-up duration: 5.5 years
UK
Primary Prevention Project, 2001
aspirin 100 mg/d
versus
no aspirin (open control)
men and women aged 50 years or greater, with at least one of the major recognised cardiovascular risk factors.Open
Follow-up duration: 3.6 y
Italy
aspirin versus placebo
AAA, 2009
ISRCTN66587262
aspirin 100mg daily
versus
placebo
men and women aged 50 to 80 years with asymptomatic atherosclerosis detected by low ankle brachial index (<=0.95)double blind
Follow-up duration: 8.2 y (mean)
UK, Scotland
ASPREE, 2018
NCT01038583

versus
ASCEND, 2018
NCT00135226

versus
Physicians Health Study, 1989
NCT00000500
aspirin 325 mg every other day
versus
placebo
Healthy mendouble blind
Follow-up duration: 60.2 months
Thrombosis Prevention Trial, 1998
NCT00000614
aspirin 75 mg/d (controlled release)
versus
placebo
Men at high risk of CHDdouble blind
Follow-up duration: median 6.8y
UK
HOT, 1998
aspirin 75 mg daily
versus
placebo
patients aged 50-80 with hypertension and diastolic blood pressure between 100 mmHG and 115 mmHGDouble blind
Follow-up duration: mean 3.8 y (range 3.3-4.9y)
Europe, North and South America, and Asia
Women’s Health Study, 2005
aspirin 100mg daily
versus
placebo
initially healthy women 45 years of age or olderDouble blind
Follow-up duration: 10.1 y mean (range 8.2 to 10.9
clopidogrel versus aspirin
CAPRIE, 1996
clopidogrel 75 mg once daily
versus
aspirin 325 mg once daily
patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial diseaseDouble blind
Follow-up duration: mean 1.91 years
16 countries
clopidogrel versus placebo (on top aspirin)
CHARISMA, 2006
NCT00050817
clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day)
versus
placebo plus low-dose aspirin
patients with either clinically evident cardiovascular disease or multiple risk factorsDouble blind
Follow-up duration: median 28 months
32 countries
ticagrelor versus placebo (on top aspirin)
PEGASUS 60mg, 2015
NCT01225562
ticagrelor at a dose of 60 mg twice daily
versus
placebo
patients who had had a myocardial infarction 1 to 3 years earlierdouble-blind
Follow-up duration: 2.75 y (median)
PEGASUS 90mg, 2015
NCT01225562
ticagrelor at a dose of 90 mg twice daily
versus
patients who had had a myocardial infarction 1 to 3 years earlier double-blind
Follow-up duration: 2.75 y (median)
vorapaxar versus placebo (on top aspirin)
TRA-2P TIMI 50, 2012
NCT00526474
vorapaxar (SCH 530348) 2.5-mg daily
versus
placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel)
patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease)double-blind
Follow-up duration: 2.5 y (median)

  Options


in first

in second

  Filter